Related Experiment Video

Updated: Oct 17, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.6K

Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data

Eleonora Tamborini Permunian1, Nicoletta Riva, Luigina Guasti

  • 1University of Insubria, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine , U.O. Medicina Interna 1, Ospedale di Circolo, viale Borri 57, 21100 Varese , Italy +39 0332 278831 ; +39 0332 278229 ; alessandro.squizzato@uninsubria.it.

Expert Opinion on Drug Metabolism & Toxicology
|March 3, 2015
PubMed

Insights

Cangrelor, an intravenous P2Y12 inhibitor, offers rapid platelet inhibition but did not outperform standard therapy in percutaneous coronary intervention. It showed promise as a bridging therapy for coronary artery bypass graft surgery.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Dual antiplatelet therapy is standard for acute coronary syndromes and recent coronary stents.
  • P2Y12 receptor antagonists reduce ischemic events but increase bleeding risk.
  • Cangrelor is a novel, intravenous, short-acting, reversible P2Y12 inhibitor for arterial thrombosis.

Purpose of the Study:

  • To evaluate the pharmacological characteristics and clinical utility of cangrelor.
  • To assess cangrelor's efficacy and safety in patients with coronary artery diseases.

Main Methods:

  • Literature search of PubMed for studies on cangrelor's pharmacology and clinical trials.
  • Review of clinical trial data for percutaneous coronary intervention and coronary artery bypass graft settings.

Main Results:

  • Cangrelor provides rapid and complete platelet aggregation inhibition with a fast offset, beneficial for bleeding.
  • Intravenous administration suits patients unable to take oral medications.
  • Clinical trials in percutaneous coronary intervention did not demonstrate superiority over standard antiplatelet therapy.

Conclusions:

  • Cangrelor's role in percutaneous coronary intervention requires further assessment.
  • Cangrelor demonstrated promising results as a bridging therapy for coronary artery bypass graft surgery.
Abstract

Keywords:
P2Y12 inhibitoracute coronary syndromecangrelorpercutaneous coronary interventionpharmacodynamicspharmacokinetics

More Related Videos

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury08:39

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury

Published on: September 7, 2018

9.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...